[HTML][HTML] Metallic nanoparticles for cancer immunotherapy

ER Evans, P Bugga, V Asthana, R Drezek - Materials Today, 2018 - Elsevier
Cancer immunotherapy, or the utilization of the body's immune system to attack tumor cells,
has gained prominence over the past few decades as a viable cancer treatment strategy …

Cytokines in cancer immunity and immunotherapy

MJ Smyth, E Cretney, MH Kershaw… - Immunological …, 2004 - Wiley Online Library
The concept that the immune system recognizes and controls cancer was first postulated
over a century ago, and cancer immunity has continued to be vigorously debated and …

Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine

SK Libutti, GF Paciotti, AA Byrnes, HR Alexander Jr… - Clinical cancer …, 2010 - AACR
Purpose: A novel nanomedicine, CYT-6091, constructed by simultaneously binding
recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol …

Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery

GF Paciotti, L Myer, D Weinreich, D Goia, N Pavel… - Drug …, 2004 - Taylor & Francis
Colloidal gold, a sol comprised of nanoparticles of Au 0, has been used as a therapeutic for
the treatment of cancer as well as an indicator for immunodiagnostics. However, the use of …

Anti‐cancer therapy with TNF α and IFN γ: A comprehensive review

J Shen, Z Xiao, Q Zhao, M Li, X Wu, L Zhang… - Cell …, 2018 - Wiley Online Library
Tumour necrosis factor alpha (TNF α) and interferon gamma (IFN γ) were originally found to
be produced by inflammatory cells and play important roles in the immune system and …

Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)

F Curnis, A Sacchi, L Borgna, F Magni, A Gasparri… - Nature …, 2000 - nature.com
The clinical use of tumor necrosis factor α (TNF) as an anticancer drug is limited to local
treatments because of its dose-limiting systemic toxicity. We show here that murine TNF …

Tumor necrosis factor, cancer and anticancer therapy

S Mocellin, CR Rossi, P Pilati, D Nitti - Cytokine & growth factor reviews, 2005 - Elsevier
Tumor necrosis factor (TNF) is being utilized as an antineoplastic agent for the treatment of
patients with locally advanced solid tumors. However, its role in cancer therapy is debated …

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results

JM Herman, AT Wild, H Wang, PT Tran… - Journal of Clinical …, 2013 - ascopubs.org
Purpose TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to
tumor cells by gene transfer. We herein report final results of the largest randomized phase …

Selective targeted delivery of TNFα to tumor blood vessels

L Borsi, E Balza, B Carnemolla, F Sassi, P Castellani… - Blood, 2003 - ashpublications.org
We sought to enhance the selective toxicity of tumor necrosis factor α (TNFα) to permit its
systemic use in cancer therapy. Because ligand-targeted therapeutics have proven …

Gastrointestinal stromal tumors: from a surgical to a molecular approach

CR Rossi, S Mocellin, R Mencarelli… - … Journal of Cancer, 2003 - Wiley Online Library
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
digestive tract. These tumors span a wide clinical spectrum from benign to malignant and …